Dare Bioscience (DARE) announced that providers in select states can now begin prescribing DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women to enhance genital blood flow and arousal response. “When Viagra was approved in 1998, it revolutionized sexual medicine for men. But for women, comparable progress on enhancing the natural arousal sensations has stalled for nearly three decades,” said Sabrina Martucci Johnson, President and CEO of Dare Bioscience. “We believe DARE to PLAY represents a long overdue correction, giving women an option to reconnect with their own bodies, their pleasure, and their confidence, using science that finally recognizes their needs.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Strategic Realignment and Growth Potential: Justifying a Buy Rating for Daré Bioscience
- Daré Bioscience Gains Full Control Over Ovaprene
- Dare Bioscience announces return of rights to Oveprene
- Dare Bioscience receives $3.6M in additional grant funding
- Daré Bioscience’s Promising Growth and Product Launches Justify Buy Rating